Gold prices briefly hit record high over $3,500/oz on fiscal, tariff concerns
Thomas Trimarchi, President and CFO of BridgeBio Pharma, Inc. (NASDAQ:BBIO), sold a total of 17,353 shares of common stock on August 18th, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as the stock trades near its 52-week high of $51.86, having delivered an impressive 94% return over the past year. The sales were executed in two tranches, with prices ranging from $50.1437 to $50.9439, resulting in total proceeds of approximately $871,722.
Specifically, 15,380 shares were sold at a weighted average price ranging from $49.76 to $50.75 per share, and 1,973 shares were sold at a weighted average price ranging from $50.83 to $50.95 per share.
On August 16th, Trimarchi also disposed of 21,317 shares of BridgeBio Pharma common stock at a price of $51.32. These shares, valued at $1,093,988, were withheld to cover tax obligations related to the vesting of restricted stock units.
Following these transactions, Trimarchi directly owns 463,318 shares of BridgeBio Pharma.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 31, 2025.
In other recent news, BridgeBio Pharma reported its second-quarter 2025 earnings, revealing a significant revenue increase. The company achieved a revenue of $110.6 million, which exceeded the forecast of $99.72 million by 10.87%. However, the earnings per share fell short of expectations, with a loss of $0.95 compared to the anticipated loss of $0.75. Attruby sales played a crucial role, with sales doubling in the second full quarter of availability, as noted by TD Cowen. The firm reiterated its Buy rating and maintained a $60.00 price target on BridgeBio Pharma due to this strong performance. Meanwhile, Oppenheimer raised its price target for the company to $61.00, following second-quarter Attruby sales of $71.5 million, which surpassed both Oppenheimer’s estimate and consensus expectations. These developments highlight the company’s ongoing momentum in its sales performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.